Severe acute respiratory syndrome (SARS) is a serious respiratory illness caused by a new member of the coronavirus family \[[@R1]--[@R3]\]. Since emerging in China\'s Guangdong province in November 2002, SARS has spread to at least 28 countries and regions in Asia, Europe, and North America, infecting \>8000 people and killing \>800 (as of 11 July 2003). The incubation period of SARS is usually 2--10 days, and the clinical manifestation of SARS is characterized by a high fever (temperature \>38°C); chills; rigors; myalgias; dry, nonproductive cough; and dizziness. At the onset of fever, the majority of patients demonstrate air-space consolidation, with either unilateral or bilateral involvement \[[@R4]--[@R9]\]. In patients who experience clinical deterioration, serial chest radiographs show progression of pulmonary infiltrates ∼7--10 days after presentation \[[@R4]--[@R10]\]. The fatality rate seems to vary in different age groups and is currently estimated to be 13.2% for patients \<60 years of age and 43.3% for patients ⩾60 of age \[[@R11]\].

Through the collaborative effort of scientists worldwide, exceedingly rapid progress has been made in the identification and sequencing of SARS\'s etiologic agent, a novel coronavirus that is genetically and serologically distinct from known strains of the same family \[[@R1]--[@R3], [@R12]--[@R14]\]. Recent studies of cynomolgus monkeys inoculated with this new coronavirus have revealed symptoms and histopathological findings similar to those in humans with SARS \[[@R15]\], providing further evidence that the coronavirus in question is the causative agent of SARS. In addition, the genetic characterizations of multiple strains that have been identified in various regions around the world seem to suggest that this novel coronavirus does not mutate as quickly as HIV or hepatitis C virus, raising optimism about the development of therapies and vaccines in the future. However, the underlying mechanism by which this new coronavirus causes SARS remains unknown.

***Subjects, materials, and methods.*** Between March and April 2003, we enrolled 98 patients who were in the acute stage of SARS and 25 patients who had recovered from SARS, according toWorld Health Organization criteria (<http://www.who.int/csr/sars/casedefinition/en>), at the Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing. Patients were treated at the hospital under the guidelines of the ethical review committee. Patients who were merely suspected of having SARS or who were deemed to probably have SARS were not included in the study. Patients in the acute stage of SARS were defined as those in the first week of the illness; recovered patients were defined as those free from the illness after ∼1 month of recovery. (Most patients with SARS take ∼1 month to recover, with the resolution of all symptoms observed during the acute phase. Once recovered, patients regain a normal body temperature, experience no cough or chest pain, and have normal chest radiograph findings.) The average age (±SD) of the patients in the acute stage of SARS was 40 ± 16, whereas that of patients who had recovered from SARS was 41 ± 15. All of these individuals, it was confirmed, had come into close contact with people with SARS. The patients\' temperatures were between 38°C and 40°C at the time of diagnosis. Fifty-seven percent of the patients had developed dry cough or light-white sputum, 36% had shortness of breath, and 62% had hypoxia. Chest radiographs demonstrated air-space consolidation, with unilateral involvement in 64% of patients and bilateral involvement in 29% of patients. Most of the patients had relatively normal liver and renal functions. In addition, all of the participating patients were antibody and antigen negative for HIV- 1, cytomegalovirus (CMV), and Epstein-Barr virus (EBV). None of the patients received any kind of treatment before blood samples were collected.

For purposes of comparison, blood samples were also obtained from 32 HIV-1-positive patients, 11 CMV-positive patients, and 6 EBV-positive patients. All of these patients were singly infected with their respective viruses and were in the acute (or early) stage of infection. The HIV-1-positive individuals selected for the study were asymptomatic and were not receiving any antiretroviral treatment. Their CD4 T cell counts were \>400 cells/mL of blood at the time of diagnosis. The acute status was determined by an incomplete or evolving pattern in serum antibody reaction against HIV-1 antigens (bioMérieux and Genelabs), as described elsewhere \[[@R16], [@R17]\]. Acute CMV infections were identified using an indirect immunofluorescence assay that detected pp65 CMV matrix protein, and acute EBV infections were detected by anti- EBV IgM in serum using a commercial detection kit. Additional blood samples were obtained from 56 healthy individuals who were on the hospital staff or who were blood donors.

Peripheral blood CD3, CD4, and CD8 T cell; B cell; and NK cell counts were measured directly from 100 µL of whole blood \[[@R16], [@R18], [@R19]\]. Cocktails of monoclonal antibodies (MAbs) (Beckman- Coulter) specific for CD3, CD4, and CD8 cells were used. For B cells, a mouse anti-human CD19 MAb was used, whereas for NK cells, a mouse anti-human CD16 and CD56 MAb was used. The same isotype control MAb was used. All of these antibodies were purchased from Immunotech. After incubation for 20 min at room temperature, the red blood cells were lysed by the addition of 500 µL of Optilyse C (Beckman-Coulter), followed by incubation for 8 min at room temperature. After being washed thoroughly with PBS, antibody-stained cells were analyzed by use of flow cytometry (EPICS-XL flow cytometer; Beckman-Coulter).

***Results.*** Using flow cytometry, we compared the absolute numbers and percentages of CD3, CD4, and CD8 T cells in samples from the 98 patients in the acute stage of SARS with the T cell counts of healthy individuals, as well as with the counts of those infected singly by HIV-1, CMV, or EBV. As shown in [figure 1](#F1){ref-type="fig"}, patients with SARS clearly experienced T cell loss in peripheral blood during the acute stage of infection. The mean absolute CD3, CD4, and CD8 T cell counts in healthy individuals was 1555, 858, and 584 cells/mm^3^, respectively, whereas those in patients with SARS were markedly lower, at 549, 254, and 258 cells/mm^3^, respectively (*P* \< .0001) ([figure 1](#F1){ref-type="fig"}). The ratio of CD4 cells to CD8 cells among patients in the acute stage of SARS was 0.98. Among the 98 patients in the acute stage of SARS, 38 had CD4 counts \<200 cells/mm^3^. In some patients with SARS, absolute CD3 T cell counts were as low as 89 cells/mm^3^, and CD4 and CD8 counts were as low as 43 and 39 cells/mm^3^, respectively ([figure 1*A*](#F1){ref-type="fig"}).

Marked differences have also been observed in T cell subsets between patients in the early stage of SARS and individuals infected with HIV-1, CMV, or EBV. In contrast to the severe loss of T cell subsets found in patients with SARS, patients infected with HIV, CMV, or EBV undergo proliferative responses, which result in higher T cell percentages and absolute counts ([figure 1*B*](#F1){ref-type="fig"}) than are seen in healthy individuals. InCMVand EBV-infected patients in particular, increases in absolute CD3 and CD8 T cell counts were more profound than those in HIV-1 infected patients ([figure 1*B*](#F1){ref-type="fig"}) \[[@R20]--[@R24]\]. For instance, the mean absolute CD3 and CD8 T cell counts in patients infected with EBV were 7923 and 6224 cells/mm^3^, respectively, which were 5--10-fold higher than those in healthy individuals and 13--23-fold higher than those in patients with SARS. The absolute CD4 T cell counts in patients with HIV-1, CMV, or EBV infection, however, decreased modestly during the acute phase of infection (data not shown).

A comparison of lymphocyte subsets was also made between patients in the acute stage of SARS and those who had recovered from the illness. As shown in [figure 2](#F2){ref-type="fig"}, in the 25 subjects studied, there was a rapid and significant restoration of CD3, CD4, and CD8 T cell; B cell; and NK cell counts ∼21 days after the onset of illness. Absolute cell counts almost doubled for all of the cell subsets studied ([figure 2](#F2){ref-type="fig"}), although the percentage did not change significantly. The trend in the normalization of peripheral lymphocyte counts usually coincided with the improving clinical condition of patients with SARS.

***Discussion.*** In this report, we describe a systematic, crosssectional study of the changes of peripheral lymphocyte subsets in patients with SARS and compare the changes with those in patients infected with HIV-1, CMV, or EBV. Our results demonstrate for the first time that there is rapid and generalized lymphopenia in patients with SARS during the acute phase of infection, which is in distinct contrast to the proliferative responses seen in HIV-1-, CMV-, or EBV-infected patients. In patients who recovered from the initial SARS illness, an equally rapid and dramatic restoration of CD3, CD4, and CD8 T cell; B cell; and NK cell counts was seen in the peripheral blood.

It is intriguing to see the human immune system respond in a drastically different manner to different viral infections. Whereas HIV-1, CMV, and EBV infections lead to proliferative lymphocyte responses, other viruses---including the SARS coronavirus, the measles virus \[[@R25]\], avian influenza virus H5N1 \[[@R26]\], swine foot-and-mouth disease virus \[[@R27]\], and respiratory syncytial virus \[[@R28]\]---are associated with generalized lymphopenia. It is believed that in measles infection, the acute lymphopenia is likely due to the apoptosis of uninfected cells \[[@R25]\], whereas in H5N1, swine foot-and-mouth disease virus, and respiratory syncytial virus infection, the underlying mechanism is much less clear \[[@R26]--[@R28]\]. Currently, we know little about how the SARS coronavirus precipitates such severe lymphopenia in such a short period of time. It is possible that tissue sequestration, cell destruction in peripheral blood, or bone marrow failure singly or together play a critical role. However, given the rapid restoration of lymphocytes in peripheral blood in recovered patients, it seems that tissue sequestration may play the most important role determining lymphocyte count in peripheral blood in patients with SARS. The exact mechanism of lymphocyte sequestration, however, remains unclear.We can only speculate, on the basis of the clinical syndrome of patients with SARS, that lymphocyte infiltration and sequestration are likely occurring in the lungs, gastrointestinal tract, or lymphoid tissues. The matter of finding concrete evidence that would support this hypothesis, and indeed of gaining an understanding of the underlying mechanism behind SARS virus-induced lung and gastrointestinal sequelae, awaits resolution in future studies.
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